Drugs / A/17/turkey/Turkey/05/133 (H5N2)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01841918 | Jan → May 2013 | avian influenza | Mahidol University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01656356 Comparator | May → Aug 2012 | avian influenza | Mahidol University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/17/turkey/Turkey/05/133 (H5N2) | “Phase II Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers” NCT01841918 ↗1“Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 21 days apart.” NCT01656356 ↗ |
| Known as | LAIV H5N2 | “an avian H5N2 live attenuated influenza vaccine (LAIV H5N2)” PMID 28533093 ↗ May 2017 |
| Modality | Vaccine | “live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2)” NCT01656356 ↗ |
| Route | Intranasal | “will be given by intranasal route 21 days apart” NCT01656356 ↗ |